Table 1.
Baseline patient, tumor and treatment characteristics
| Factor | Total (n = 67) | GEM (n = 31) | PTX (n = 36) | P‐value |
|---|---|---|---|---|
| Age, mean ± SD | 53.0 ± 12.6 | 51.9 ± 14.3 | 53.9 ± 10.9 | 0.50† |
| Sex, n (%) | 0.77‡ | |||
| Male | 42 (62.7) | 20 (64.5) | 22 (61.1) | |
| Female | 25 (37.3) | 11 (35.5) | 14 (38.9) | |
| Age, n (%) | 0.53‡ | |||
| <65 | 52 (77.6) | 23 (74.2) | 29 (80.6) | |
| ≥65 | 15 (22.4) | 8(25.8) | 7 (19.4) | |
| Pathological type | 0.001‡ | |||
| squamous carcinoma | 64 | 31 | 33 | |
| Adenocarcinoma | 2 | 0 | 2 | |
| Neuroendocrine carcinoma | 1 | 0 | 1 | |
| Metastasis, n (%) | 0.022‡ | |||
| Lymph node | 18 (26.9) | 12 (38.7) | 6 (16.7) | |
| Distant | 42 (62.7) | 14 (45.2) | 28 (77.8) | |
| None | 7 (10.4) | 5 (16.1) | 2 (5.6) | |
| Masaoka‐Koga stage, n (%) | 0.24§ | |||
| IVa | 7 (10.4) | 5 (16.1) | 2 (5.6) | |
| IVb | 60 (89.6) | 26 (83.9) | 34 (94.4) | |
| Surgery, n (%) | 0.36‡ | |||
| No | 53 (79.1) | 23 (74.2) | 30 (83.3) | |
| Yes | 14 (20.9) | 8 (25.8) | 6 (16.7) | |
| Radiotherapy, n (%) | 0.020‡ | |||
| No | 34 (50.7) | 11 (35.5) | 23 (63.9) | |
| Yes | 33 (49.3) | 20 (64.5) | 13 (36.1) |
†
Student's t‐test.
‡
Pearson's chi‐square test.
§
Fisher's exact test.
GEM, gemcitabine‐based chemotherapy; PTX, paclitaxel‐based chemotherapy; SD, standard deviation.